Company intelligence / Profile preview
Hengrui
Lianyungang, Jiangsu, Chinahengrui.com ↗
- Ownership
- Private
- Employees
- ~26000
- Development stage
- Commercial
01
Overview
Hengrui commercializes 24 new molecular entity drugs and 4 other innovative drugs in China, and has more than 100 innovative candidates in clinical development, supported by over 400 active clinical studies worldwide, with several global and Chinese regulatory designations and recent U.S. orphan drug status for oncology.
- Therapeutic areas
- ImmunologyEndocrinologyOphthalmologyInfectious DiseasesDermatologyPulmonologyCardiovascularOncologyNeurology
- Modalities
- Small moleculeMonoclonal antibodyAntibody-drug conjugateProteolysis-targeting chimera therapyPeptidesmRNA-based drugsRadiopharmaceuticalBispecific monoclonal antibody
- Industry
- Pharma
02
Drug pipeline
37 assets36 more assets in the full pipeline.
03
Partnerships
GSKMerck
Beyond the preview
Go deeper on Hengrui.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hengrui.